N-(phenethylsulfonyl)-D-serine | 406950-99-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(phenethylsulfonyl)-D-serine
• 英文别名: (2R)-3-hydroxy-2-(2-phenylethylsulfonylamino)propanoic acid
• CAS: 406950-99-0
• 化学式: C₁₁H₁₅NO₅S
• mdl: MFCD25020496
• 分子量: 273.31
• InChiKey: IZUNIPUWLJYEGS-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(phenethylsulfonyl)-D-serine 在 dimethyl azodicarboxylate 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 3.33h， 以37%的产率得到2-Phenyl-ethanesulfonic acid ((R)-2-oxo-oxetan-3-yl)-amide
  参考文献：
  名称：

  Serine and Threonine β-Lactones:  A New Class of Hepatitis A Virus 3C Cysteine Proteinase Inhibitors

  摘要：

  Hepatitis A virus (HAV) 3C enzyme is a cysteine proteinase essential for viral replication and infectivity and represents a target for the development of antiviral drugs. A number of serine and threonine beta-lactones were synthesized and tested against HAV 3C proteinase. The D-N-Cbz-serine beta-lactone 5a displays competitive reversible inhibition with a K-i value of 1.50 x 10(-6) M. Its enantiomer, L-N-Cbz-serine beta-lactone 5b is an irreversible inactivator with 0.70 min(-1), K, = 1.84 x 10(-4) M and k(inact)/K-I = 3800 M-1 min(-1). Mass spectrometry and HMQC NMR studies using C-13-labeled 5b show that inactivation of the enzyme occurs by nucleophilic attack of the cysteine thiol (Cys-172) at the beta-position of the oxetanone ring. Although the N-Cbz-serine beta-lactones 5a and 5b display potent inhibition, other related analogues with an N-Cbz side chain, such as the five-membered ring homoserine gamma-lactones 14a and 14b, the four-membered ring beta-lactam 33, 2-methylene oxetane 34, cyclobutanone 36, and 3-azetidinone 39, fail to give significant inhibition of HAV 3C proteinase, thus demonstrating the importance of the beta-lactone ring for binding.

  DOI：

  10.1021/jo0109016
• 作为产物：
  描述：

  反-β-苯乙烯磺酰氯 在 10percent Pd/C lithium hydroxide 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 N-(phenethylsulfonyl)-D-serine
  参考文献：
  名称：

  Serine and Threonine β-Lactones:  A New Class of Hepatitis A Virus 3C Cysteine Proteinase Inhibitors

  摘要：

  Hepatitis A virus (HAV) 3C enzyme is a cysteine proteinase essential for viral replication and infectivity and represents a target for the development of antiviral drugs. A number of serine and threonine beta-lactones were synthesized and tested against HAV 3C proteinase. The D-N-Cbz-serine beta-lactone 5a displays competitive reversible inhibition with a K-i value of 1.50 x 10(-6) M. Its enantiomer, L-N-Cbz-serine beta-lactone 5b is an irreversible inactivator with 0.70 min(-1), K, = 1.84 x 10(-4) M and k(inact)/K-I = 3800 M-1 min(-1). Mass spectrometry and HMQC NMR studies using C-13-labeled 5b show that inactivation of the enzyme occurs by nucleophilic attack of the cysteine thiol (Cys-172) at the beta-position of the oxetanone ring. Although the N-Cbz-serine beta-lactones 5a and 5b display potent inhibition, other related analogues with an N-Cbz side chain, such as the five-membered ring homoserine gamma-lactones 14a and 14b, the four-membered ring beta-lactam 33, 2-methylene oxetane 34, cyclobutanone 36, and 3-azetidinone 39, fail to give significant inhibition of HAV 3C proteinase, thus demonstrating the importance of the beta-lactone ring for binding.

  DOI：

  10.1021/jo0109016

文献信息

• PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN
  申请人：Shiseido Company, Limited

  公开号：EP1884230A1

  公开（公告）日：2008-02-06

  The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin -inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and to further provide an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor agent, pore-shrinking agent, or rough skin preventing/amaliorating agent comprises one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof. The external composition for skin comprises the one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent.

  该发明提供了一种具有角化不全抑制、收缩毛孔或防止/改善粗糙皮肤功能的抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂，不会引起感觉刺激等安全问题，非常安全，并进一步提供了一种外用皮肤组合物，其中添加了具有上述功能的化合物。角化不全抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂包括从α-氨基酸衍生物和其盐组成的群中选择的一种、两种或更多化合物。外用皮肤组合物包括从α-氨基酸衍生物和其盐组成的群中选择的一种、两种或更多化合物，作为上述角化不全抑制剂、收缩毛孔剂或防止/改善粗糙皮肤剂。
• INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION
  申请人：CORVAS INTERNATIONAL, INC.

  公开号：EP1100814A2

  公开（公告）日：2001-05-23
• [EN] INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION<br/>[FR] INHIBITEURS D'UROKINASE ET DE LA FORMATION DE VAISSEAUX SANGUINS
  申请人：CORVAS INT INC

  公开号：WO2000005245A2

  公开（公告）日：2000-02-03

  Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
• [EN] NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION<br/>[FR] INHIBITEURS NON COVALENTS DE L'UROKINASE ET DE LA FORMATION DE VAISSEAUX SANGUINS
  申请人：CORVAS INT INC

  公开号：WO2002014349A2

  公开（公告）日：2002-02-21

  Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have P1 a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
• Serine and Threonine β-Lactones:  A New Class of Hepatitis A Virus 3C Cysteine Proteinase Inhibitors
  作者：Manjinder S. Lall、Yeeman K. Ramtohul、Michael N. G. James、John C. Vederas

  DOI：10.1021/jo0109016

  日期：2002.3.1

  Hepatitis A virus (HAV) 3C enzyme is a cysteine proteinase essential for viral replication and infectivity and represents a target for the development of antiviral drugs. A number of serine and threonine beta-lactones were synthesized and tested against HAV 3C proteinase. The D-N-Cbz-serine beta-lactone 5a displays competitive reversible inhibition with a K-i value of 1.50 x 10(-6) M. Its enantiomer, L-N-Cbz-serine beta-lactone 5b is an irreversible inactivator with 0.70 min(-1), K, = 1.84 x 10(-4) M and k(inact)/K-I = 3800 M-1 min(-1). Mass spectrometry and HMQC NMR studies using C-13-labeled 5b show that inactivation of the enzyme occurs by nucleophilic attack of the cysteine thiol (Cys-172) at the beta-position of the oxetanone ring. Although the N-Cbz-serine beta-lactones 5a and 5b display potent inhibition, other related analogues with an N-Cbz side chain, such as the five-membered ring homoserine gamma-lactones 14a and 14b, the four-membered ring beta-lactam 33, 2-methylene oxetane 34, cyclobutanone 36, and 3-azetidinone 39, fail to give significant inhibition of HAV 3C proteinase, thus demonstrating the importance of the beta-lactone ring for binding.